0.46
+5.25%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Outlook Therapeutics
From its filings with the US Securities and Exchange Commission
Outlook Therapeutics is based in Iselin, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker OTLK. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 30 September 2025, it reported revenue of $1.4m and a net loss of $62.4m. At that date it held total assets of $18.6m and shareholders' equity of −$32.2m.
We are a biopharmaceutical company that has developed ONS-5010/LYTENAVATM as the first ophthalmic formulation of bevacizumab approved by the European Commission in the European Union, or EU, and the Medicines and Healthcare products Regulatory Agency, or MHRA, in the United Kingdom, or UK, for use in adults for the treatment of wet age-related macular degeneration, or wet AMD. In June 2025, we launched directly into the initial markets of Germany and the UK. Additionally, our Biologics License Application, or BLA, is currently under review at the U.S. Food and Drug Administration, or FDA, for the use of ONS-5010/LYTENAVA as a treatment for wet AMD in the United States. If approved by the FDA., our goal is to also launch directly in the United States as the first and only approved ophthalmic bevacizumab for the treatment of wet AMD. In addition to Europe and the United States., we may seek approval to launch ONS-5010/LYTENAVA the product in other markets. ONS-5010/LYTENAVA is manufactured in the United States.
Bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody, or mAb, that inhibits VEGF and associated angiogenic activity. Prior to the approval of ONS-5010/LYTENAVA in the EU and UK, bevacizumab had only been approved for use in the treatment of various forms of cancer and had not been optimized for use in the treatment of retina diseases.
Quoted from its 10-K, filed 19 Dec 2025. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 13 Jun 2016
- Employees
- 17
- Website
- oncobiologics.com ↗
- Head office
- 111 S. WOOD AVENUE, ISELIN, NJ, 08830
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Faisal SukhtianIndependent Chairman of the Board$113,000
- Mr. Robert JahrPresident, Chief Executive Officer, Director, since 2025
- Mr. Lawrence KenyonChief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director, since 2015$634,597
- Mr. Ralph ThurmanLead Independent Director, since 2018$242,500
- Prof. Dr. Gerd AuffarthIndependent Director$79,000
- Mr. Julian GangolliIndependent Director$112,500
- Mr. Yezan HaddadinIndependent Director$110,000
- Dr. Julia HallerIndependent Director$79,000
- Mr. Kurt HilzingerIndependent Director$95,000
- Mr. Andong HuangIndependent Director$75,000
- Ms. Jenene ThomasInvestor Relations, since 2021
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 22
- Environment
- 20
- Social
- 41
- Governance
- 3
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Outlook Therapeutics has FDA-approved ONS-5010/LYTENAVA for retinal indications including wet AMD and DME.
- The company's BioSymphony Platform identifies eight biosimilar product candidates targeting immunology and oncology.
- ONS-3010, an adalimumab biosimilar, has initiated Phase III preparatory activities for commercialization.
Weaknesses
- Outlook Therapeutics employs only 14 full-time employees, limiting operational capacity.
- The company's focus on biosimilars in immunology and oncology may face intense competition.
- ONS-1050, a trastuzumab biosimilar, remains in preclinical development without FDA approval.
Opportunities
- ONS-3010's Phase III preparatory activities could lead to FDA approval and market entry.
- The growing demand for biosimilars in the US market presents expansion potential.
- The BioSymphony Platform's eight product candidates offer multiple revenue streams.
Threats
- The FDA approval process for biosimilars may delay market entry for ONS-3010 and ONS-1045.
- Competition from established biopharmaceutical companies in the oncology sector.
- The high costs of clinical trials for biosimilars could strain financial resources.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.